GLP-1 medications such as Ozempic, Ro, and Mounjaro have become among the most talked-about topics in health and wellness. Originally developed to help regulate blood sugar in people with type 2 diabetes, they’ve since become a cornerstone of modern weight-loss management. Now, new research from the University of California San Diego suggests they may also be linked to lower colon cancer mortality rates.
In a study analyzing 6,871 patients with colon cancer, researchers found that those taking GLP-1 medications were more likely to live longer than those who weren’t. Specifically, the five-year mortality rate decreased to 15.5 percent for GLP-1 users, compared to 37.1 percent for non-users.
Published on November 11, the study used data from the University of California Health Data Warehouse, with patient identities protected for privacy. Even after adjusting for factors such as disease severity and body mass index (BMI), the results remained consistent: patients taking GLP-1s had longer survival.
The results appeared most beneficial for patients with higher BMIs. According to the study, the benefit persisted but was most significant in those with a BMI greater than 35. An article published by UC San Diego Today notes that researchers believe GLP-1 drugs may help counteract the inflammatory and metabolic conditions that can worsen colon cancer outcomes.
As with all emerging research, further studies are needed to determine whether the findings indicate a direct link between GLP-1 use and life expectancy in colon cancer patients. Still, the results add to the growing body of evidence suggesting these medications may have benefits that extend well beyond weight loss.
